In a statement, Bristol-Myers Squibb Co and Eisai Co said, they had entered into an agreement to jointly develop and market an experimental cancer drug worth up to $3.10 billion. Bristol-Myers would pay $650 million, including for research and development… Read More ›
While the deal will boost Ipen’s cancer drug portfolio, Merrimack’s shareholders will receive a special dividend as an outcome of the deal. France-based drug manufacturer Ipsen SA, has disclosed it will be acquiring some assets from its U.S. peer Merrimack… Read More ›
manageria.biz 